Myelodysplastic syndromes (MDS) comprise a diverse group of clonal and malignant
myeloid disorders characterized by ineffective hematopoiesis, resultant peripheral …

Background Myelodysplastic syndromes are a diverse and common group of chronic
hematologic cancers. The identification of new genetic lesions could facilitate new …

Myelodysplastic syndrome (MDS) is a clonal disease characterized by multilineage
dysplasia, peripheral blood cytopenias, and a high risk of transformation to acute myeloid …

A prospective multicenter observational study of decitabine treatment in Korean patients with
myelodysplastic syndrome - PMC Back to Top Skip to main content NIH NLM Logo Access keys …

Background: This study was undertaken to evaluate the prognostic value of the WHO
Classification‐Based Prognostic Scoring System (WPSS) and to compare it with that of the …

Introduction The objective of this study was to evaluate the efficacy and safety of decitabine
in Chinese patients with myelodysplastic syndrome (MDS). Methods Patients (≥ 18 years) …

We analyzed the role of antibiotic prophylaxis during decitabine treatment for MDS. The
primary endpoint was the incidence of febrile episodes. The total number of decitabine …

Acquired elliptocytosis is a known but rarely described abnormality in the myelodysplastic
syndromes (MDS). Here we report the case of an elderly male who was admitted to the …

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms.
Chromosomal abnormalities have been detected in 40–70% patients with primary MDS and …

In 2008, the WHO combined the former categories RCMD (refractory cytopenia with
multilineage dysplasia) and RCMD-RS (ring sideroblasts≥ 15%). We studied the clinical …